Printer Friendly

Atossa Genetics reports Q2 EPS (80c) vs. ($5.08) a year ago as restated.

Steven Quay, Atossa Genetics' President and CEO commented, "During the quarter we were very pleased to have achieved our primary endpoint in our Phase 2 trial of topical Endoxifen to reduce mammographic breast density. We are now focusing our efforts on the oral formulation of Endoxifen and are developing a modified-release oral tablet which is being tested in a Phase 1 study and that we plan to use in a Phase 2 study to reduce MBD. The Phase 2 study is scheduled to start in the fourth quarter and should be completed by mid-2020. We completed the quarter with $17.1M in cash, which will enable us to continue to make clinical progress with our programs."

COPYRIGHT 2019 The Fly
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:The Fly
Article Type:Financial report
Date:Aug 13, 2019
Previous Article:Spotify in talks with Apple over Siri voice commands, Information reports.
Next Article:CBS, Viacom to combine in all-stock merger to create ViacomCBS.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters